MedTrace Logo

A Study in Participants With Diabetic Kidney Disease

NCT01113801 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 417

Last updated 2019-09-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.

Conditions

  • Diabetic Kidney Disease
  • Diabetic Nephropathy
  • Diabetic Glomerulosclerosis

Interventions

DRUG

LY2382770

Subcutaneous injection given monthly for 12 months

DRUG

Placebo

Subcutaneous injection given monthly for 12 months

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-05-31
Completion
2014-07-31

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Hungary
  • Israel
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01113801 on ClinicalTrials.gov